Amylyx Pharmaceuticals, Inc. financial data

Symbol
AMLX on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 03 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1230% % 156%
Debt-to-equity 10% % -61%
Return On Equity -58% % 55%
Return On Assets -52% % 48%
Operating Margin 23660% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 110,536,944 shares 24%
Common Stock, Shares, Outstanding 109,884,502 shares 60%
Entity Public Float $518,200,000 USD -100%
Common Stock, Value, Issued $11,000 USD 57%
Weighted Average Number of Shares Outstanding, Basic 94,565,567 shares 39%
Weighted Average Number of Shares Outstanding, Diluted 94,565,567 shares 39%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
Research and Development Expense $90,404,000 USD -13%
Costs and Expenses $153,291,000 USD -62%
Operating Income (Loss) $153,291,000 USD 51%
Nonoperating Income (Expense) $8,602,000 USD -32%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $144,689,000 USD 52%
Income Tax Expense (Benefit) $46,000 USD
Net Income (Loss) Attributable to Parent $144,735,000 USD 52%
Earnings Per Share, Basic -1.53 USD/shares 65%
Earnings Per Share, Diluted -1.53 USD/shares 65%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $226,651,000 USD 193%
Marketable Securities, Current $90,328,000 USD -8.9%
Accounts Receivable, after Allowance for Credit Loss, Current $88,000 USD -80%
Assets, Current $323,671,000 USD 71%
Property, Plant and Equipment, Net $310,000 USD -68%
Operating Lease, Right-of-Use Asset $5,181,000 USD 193%
Other Assets, Noncurrent $2,500,000 USD 419%
Assets $332,645,000 USD 72%
Accounts Payable, Current $3,519,000 USD 20%
Employee-related Liabilities, Current $10,055,000 USD 0.63%
Accrued Liabilities, Current $17,910,000 USD -25%
Liabilities, Current $22,688,000 USD -20%
Operating Lease, Liability, Noncurrent $4,698,000 USD 915%
Liabilities $27,386,000 USD -5.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax $404,000 USD
Retained Earnings (Accumulated Deficit) $751,427,000 USD -24%
Stockholders' Equity Attributable to Parent $305,259,000 USD 85%
Liabilities and Equity $332,645,000 USD 72%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $39,824,000 USD -8044%
Net Cash Provided by (Used in) Financing Activities $65,662,000 USD 50024%
Net Cash Provided by (Used in) Investing Activities $43,659,000 USD -5431%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 109,884,502 shares 60%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $17,624,000 USD -5121%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $227,636,000 USD 189%
Deferred Tax Assets, Valuation Allowance $199,595,000 USD 26%
Deferred Tax Assets, Gross $201,024,000 USD 26%
Operating Lease, Liability $5,957,000 USD 201%
Depreciation $156,000 USD -50%
Payments to Acquire Property, Plant, and Equipment $11,000 USD -84%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $144,239,000 USD 52%
Lessee, Operating Lease, Liability, to be Paid $7,698,000 USD 273%
Property, Plant and Equipment, Gross $1,864,000 USD -20%
Operating Lease, Liability, Current $1,259,000 USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,408,000 USD 196%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,850,000 USD 17%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,741,000 USD 2023%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,444,000 USD
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $4,318,000 USD 15%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,480,000 USD
Operating Lease, Payments $100,000 USD
Deferred Tax Assets, Net of Valuation Allowance $1,429,000 USD 135%
Share-based Payment Arrangement, Expense $27,645,000 USD -16%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%